I
InflaRx NV D
D
IFRX
1.73100
USD
-0.13
(-6.94%)
مغلق
حجم التداول
4,276
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
117,270,282
الأخبار المقالات
العنوان: InflaRx NV
القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.